Scholar Rock Has Dosed The First Participants In The Phase 2 EMBRAZE Proof-of-concept Trial Of Apitegromab To Preserve Lean Muscle Mass In Individuals Living With Obesity And On Background Therapy Of A GLP-1 Receptor Agonist
Scholar Rock Has Dosed The First Participants In The Phase 2 EMBRAZE Proof-of-concept Trial Of Apitegromab To Preserve Lean Muscle Mass In Individuals Living With Obesity And On Background Therapy Of A GLP-1 Receptor Agonist
學者石已經對在胰高血糖素受體激動劑（GLP-1）背景治療下的肥胖病人進行了一項階段2的EMBRAZE概念驗證試驗，以維護肌肉質量。
The trial will also evaluate the effects of apitegromab on the durability of weight loss upon withdrawal of GLP-1 RA therapy. The results from this trial will inform the development of SRK-439, a novel investigational selective myostatin inhibitor optimized for the treatment of cardiometabolic disorders, including obesity.
該試驗還將評估對藥物GLP-1RA撤退後體重減輕的持久性對apitegromab的影響。該試驗的結果將爲SRK-439的開發提供參考，SRK-439是一種新型的選擇性肌肉生成素抑制劑，用於治療心血管代謝性疾病，包括肥胖症。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。